Share tips: Play the global food supply crunch
America is suffering its worst drought in decades. That's bad news for this agricultural giant - but good news for patient investors, says Paul Hill.
America's Midwest is suffering a heatwave that has caused the worst drought for 24 years and is threatening the nation's crops. Corn prices are surging and the shares of US grain processors have plunged. This spike in input costs should be treated as an opportunity for investors. The world's population of seven billion is forecast to exceed nine billion by 2050. That will see demand rising by 70%.
Meanwhile, topsoil erosion, climate change and a lack of irrigation are restricting the availability of arable land. Throw in escalating demand from biofuels, and the world could face a supply crunch. I think the recent pullback in the shares of agricultural giant Bunge offers a good entry point for patient investors.
The group buys, sells, stores, transports and processes oilseeds, grains, sugarcane, biofuels and wheat. It also produces fertilisers and animal feed. Its operations span established powerhouses like the US and rapidly expanding parts of eastern Europe and Asia.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
This global offering is enhanced by first-class storage, milling and transport facilities. Bunge manages eight sugarcane mills in Brazil. These are equipped to produce renewable electricity from ethanol that can be diverted to the national grid. Over time, power generation could generate 20% of the division's profits, providing both a source of growth and greater diversification.
Bunge (NYSE: BG), rated a BUY by Feltl and Company
Wall Street expects 2012 turnover and underlying earnings per share (EPS) of $62.7bn and $6.54 respectively, rising to $66.4bn and $7.29 in 12 months time. That puts the stock on a miserly price/earnings (p/e) ratio of less than ten. I rate the stock on a nine times earnings before interest, tax, depreciation and amortisation (EBITDA) multiple. Adjusting for $690m of preference shares and $4bn of net debt generates an intrinsic worth of around $75 per share.
Risks include volatile prices, increasing competition, geopolitical fears, foreign currency fluctuations and possible trade protectionism. Nonetheless, the long-term fundamentals are very positive. The company also offers a sound hedge against inflation in the event that quantitative easing spirals out of control. Feltl has a target price of $82, and the next quarterly earnings are due out on Wednesday 25 July.
Rating: BUY at $61.20
Paul Hill also writes a weekly share-tipping newsletter, Precision Guided Investments. See www.moneyweek.com/PGI or phone 020-7633 3634.
Sign up to Money Morning
Our team, led by award winning editors, is dedicated to delivering you the top news, analysis, and guides to help you manage your money, grow your investments and build wealth.
Paul gained a degree in electrical engineering and went on to qualify as a chartered management accountant. He has extensive corporate finance and investment experience and is a member of the Securities Institute.
Over the past 16 years Paul has held top-level financial management and M&A roles for blue-chip companies such as O2, GKN and Unilever. He is now director of his own capital investment and consultancy firm, PMH Capital Limited.
Paul is an expert at analysing companies in new, fast-growing markets, and is an extremely shrewd stock-picker.
-
Energy bills to rise by 1.2% in January 2025
Energy bills are set to rise 1.2% in the New Year when the latest energy price cap comes into play, Ofgem has confirmed
By Dan McEvoy Published
-
Should you invest in Trainline?
Ticket seller Trainline offers a useful service – and good prospects for investors
By Dr Matthew Partridge Published